Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Tirabrutinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom's Macroglobulinemia ### Output: Tirabrutinib